← Back to front page
United States · Platforms & data · MarketBeat

ArriVent BioPharma (NASDAQ:AVBP) Stock Price Target Lowered at Guggenheim

Published by MarketBeat · United States 39 min ago
Image from MarketBeat Media, LLC.
Image from MarketBeat Media, LLC. · MarketBeat

Detailed summary

Guggenheim dropped their price target on ArriVent BioPharma from $30.00 to $28.00 and set a "buy" rating for the company in a research report on Monday.

Read the full article on MarketBeat Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.marketbeat.com)

Also worth reading